RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis

Jahr

2024

Autoren

Aktas O, Ziemssen F, Ziemssen T, Klistorner A, Butzkueven H, Izquierdo G, Leocani L, Balcer LJ, Galetta SL, Castrillo-Viguera C, Bradley DP, Naylor ML, Belachew S, Franchimont N, Zhu B, Cheng W; RENEWED Investigators.

Verlag

Mult Scler Relat Disord. 2024 Nov 24;93:106185.

Link

https://doi.org/10.1016/j.msard.2024.106185

RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis

Patients with relapsing-remitting multiple sclerosis show accelerated whole brain volume and thalamic volume loss early in disease

Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice

MS brain health quality standards: a survey on the reality in clinical practice in Germany

Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study

Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study